Survival and Recurrence in Patients With Splanchnic Vein Thromboses Mallikarjun R. Thatipelli, Robert D. McBane, David O. Hodge, Waldemar E. Wysokinski  Clinical Gastroenterology and Hepatology  Volume 8, Issue 2, Pages 200-205 (February 2010) DOI: 10.1016/j.cgh.2009.09.019 Copyright © 2010 AGA Institute Terms and Conditions

Figure 1 Splanchnic venous thrombus location. Number and location of isolated venous segment thrombosis are presented. Where thrombosis extended to an additional venous segment, the number is presented in parentheses for each location. Clinical Gastroenterology and Hepatology 2010 8, 200-205DOI: (10.1016/j.cgh.2009.09.019) Copyright © 2010 AGA Institute Terms and Conditions

Figure 2 Age decile at diagnosis by gender. Differences in age distribution and gender at time of diagnosis are apparent for each venous segment involved. These data represent isolated venous thrombosis at the various locations only. Clinical Gastroenterology and Hepatology 2010 8, 200-205DOI: (10.1016/j.cgh.2009.09.019) Copyright © 2010 AGA Institute Terms and Conditions

Figure 3 Recurrent venous thromboembolism. Recurrence-free survival of patients with splanchnic vein thrombosis at 10 years (A) did not differ significantly compared with those with lower extremity DVT (P = .68). Recurrence-free survival at 10 years (B) was marginally greater for isolated venous segment involvement compared with those with multisegmental involvement (P = .07). Patients with mesenteric and hepatic vein thrombosis experienced marginally lower recurrence-free survival rates (60% and 76%, respectively) compared with splenic (97%) and portal (85%) vein thrombosis (C), but these differences have not reached statistical significance (P = .08). Recurrence-free survival at 10 years was similar for patients receiving warfarin (D) compared with those not anticoagulated. Clinical Gastroenterology and Hepatology 2010 8, 200-205DOI: (10.1016/j.cgh.2009.09.019) Copyright © 2010 AGA Institute Terms and Conditions

Figure 4 Survival. Overall survival at 10 years (A) for patients with splanchnic vein thrombosis was lower compared with DVT patients (P = .02) or age-matched and gender-matched individuals from the US white population (P = .004). Patients with isolated venous segmental involvement (B) had higher overall survival compared with those with multisegmental involvement (P < .001). Patients with splanchnic vein thrombosis and underlying active malignancy (C) had much lower survival than those without active malignancy (P < .001). Patients with isolated hepatic vein thrombosis had the highest 10-year survival rate (D), whereas patients with isolated portal vein thrombosis had the lowest (P = .045). Overall survival at 10 years was greater for patients receiving warfarin (E) compared with those not anticoagulated (P = .01). Clinical Gastroenterology and Hepatology 2010 8, 200-205DOI: (10.1016/j.cgh.2009.09.019) Copyright © 2010 AGA Institute Terms and Conditions